Biocryst Pharmaceuticals buy Royal Bank of Canada
Start price
11.04.25
/
50%
€5.91
Target price
11.04.26
€9.75
Performance (%)
18.44%
Price
29.07.25
€7.00
Summary
This prediction is currently active. The prediction currently has a performance of 18.44%. This prediction currently runs until 11.04.26. The prediction end date can be changed by Royal_Bank_of_Canada at any time. Royal_Bank_of_Canada has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Biocryst Pharmaceuticals | -5.072% | -5.072% |
| iShares Core DAX® | 0.426% | 0.647% |
| iShares Nasdaq 100 | 2.809% | 4.822% |
| iShares Nikkei 225® | 3.288% | -1.311% |
| iShares S&P 500 | 2.785% | 4.737% |
Comments by Royal_Bank_of_Canada for this prediction
In the thread Biocryst Pharmaceuticals diskutieren
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $11.00 price target on the stock.
Ratings data for BCRX provided by MarketBeat
Stopped prediction by Royal_Bank_of_Canada for Biocryst Pharmaceuticals
Biocryst Pharmaceuticals
Start price
Target price
Perf. (%)
€7.60
30.06.25
30.06.25
€11.09
30.06.26
30.06.26
-7.92%
29.07.25
29.07.25
Biocryst Pharmaceuticals
Start price
Target price
Perf. (%)
€8.90
06.05.25
06.05.25
€11.51
06.05.26
06.05.26
-21.33%
29.07.25
29.07.25
Biocryst Pharmaceuticals
Start price
Target price
Perf. (%)
€7.79
25.02.25
25.02.25
€10.47
25.02.26
25.02.26
-10.12%
29.07.25
29.07.25
Biocryst Pharmaceuticals
Start price
Target price
Perf. (%)
€6.61
05.11.24
05.11.24
€9.16
05.11.25
05.11.25
5.90%
29.07.25
29.07.25
Biocryst Pharmaceuticals
Start price
Target price
Perf. (%)
€6.95
25.09.23
25.09.23
€9.44
25.09.24
25.09.24
-2.42%
26.09.24
26.09.24